Report Detail

Pharma & Healthcare House Dust Mite Allergy - Pipeline Review, H2 2019

  • RnM3784257
  • |
  • 26 September, 2019
  • |
  • Global
  • |
  • 59 Pages
  • |
  • Global Markets Direct
  • |
  • Pharma & Healthcare

House Dust Mite Allergy - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide House Dust Mite Allergy - Pipeline Review, H2 2019, provides an overview of the House Dust Mite Allergy (Immunology) pipeline landscape.

House dust mite allergy is an allergic reaction to tiny bugs that commonly live in house dust. Symptoms include frequent sneezing, a runny, stuffy, itchy nose and irritated eyes. Asthma and eczema can also be triggered by a dust mite allergy. Symptoms often worsen when the individual comes in close proximity to disturbed dust. The predisposing factors include family history and age. Treatment includes antihistamines, decongestants and corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide House Dust Mite Allergy - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for House Dust Mite Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The House Dust Mite Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for House Dust Mite Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 4, 1, 1, 4 and 1 respectively.

House Dust Mite Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of House Dust Mite Allergy (Immunology).
- The pipeline guide reviews pipeline therapeutics for House Dust Mite Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in House Dust Mite Allergy (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates House Dust Mite Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for House Dust Mite Allergy (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for House Dust Mite Allergy (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding House Dust Mite Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Table of Contents

    List of Tables

      List of Figures

        Introduction

          Global Markets Direct Report Coverage

            House Dust Mite Allergy - Overview

              House Dust Mite Allergy - Therapeutics Development

                Pipeline Overview

                  Pipeline by Companies

                    Products under Development by Companies

                      House Dust Mite Allergy - Therapeutics Assessment

                        Assessment by Route of Administration

                          Assessment by Molecule Type

                            House Dust Mite Allergy - Companies Involved in Therapeutics Development

                              ALK-Abello AS

                                Allergy Therapeutics Plc

                                  Anergis SA

                                    ASIT Biotech SA

                                      Astellas Pharma Inc

                                        Biomay AG

                                          Genetic Immunity Inc

                                            Roxall Medizin GmbH

                                              Stallergenes Greer plc

                                                House Dust Mite Allergy - Drug Profiles

                                                  Allergan for Dust Mite Allergy - Drug Profile

                                                    Product Description

                                                      Mechanism Of Action

                                                        R&D Progress

                                                          Allergen for Allergic Asthma and House Dust Mite Allergy - Drug Profile

                                                            Product Description

                                                              Mechanism Of Action

                                                                R&D Progress

                                                                  AM-101 - Drug Profile

                                                                    Product Description

                                                                      Mechanism Of Action

                                                                        R&D Progress

                                                                          ASP-2390 - Drug Profile

                                                                            Product Description

                                                                              Mechanism Of Action

                                                                                R&D Progress

                                                                                  BM-35 - Drug Profile

                                                                                    Product Description

                                                                                      Mechanism Of Action

                                                                                        R&D Progress

                                                                                          clustoid d. pteronyssinus - Drug Profile

                                                                                            Product Description

                                                                                              Mechanism Of Action

                                                                                                R&D Progress

                                                                                                  DermAll-HDM - Drug Profile

                                                                                                    Product Description

                                                                                                      Mechanism Of Action

                                                                                                        R&D Progress

                                                                                                          hdm-ASIT - Drug Profile

                                                                                                            Product Description

                                                                                                              Mechanism Of Action

                                                                                                                R&D Progress

                                                                                                                  house dust mite (Dermatophagoides farinae) allergen extract - Drug Profile

                                                                                                                    Product Description

                                                                                                                      Mechanism Of Action

                                                                                                                        R&D Progress

                                                                                                                          PL-103 - Drug Profile

                                                                                                                            Product Description

                                                                                                                              Mechanism Of Action

                                                                                                                                R&D Progress

                                                                                                                                  standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract - Drug Profile

                                                                                                                                    Product Description

                                                                                                                                      Mechanism Of Action

                                                                                                                                        R&D Progress

                                                                                                                                          standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen extract - Drug Profile

                                                                                                                                            Product Description

                                                                                                                                              Mechanism Of Action

                                                                                                                                                R&D Progress

                                                                                                                                                  Vaccine for House Dust Mite Allergy - Drug Profile

                                                                                                                                                    Product Description

                                                                                                                                                      Mechanism Of Action

                                                                                                                                                        R&D Progress

                                                                                                                                                          House Dust Mite Allergy - Dormant Projects

                                                                                                                                                            House Dust Mite Allergy - Discontinued Products

                                                                                                                                                              House Dust Mite Allergy - Product Development Milestones

                                                                                                                                                                Featured News & Press Releases

                                                                                                                                                                  Jun 03, 2019: Targeted early treatment with ALKs ACARIZAX could improve allergic asthma treatment, allergy congress hears

                                                                                                                                                                    May 31, 2019: Stallergenes Greer will be at 2019 EAACI Congress and present the results of its phase III House Dust Mites Tablet trial

                                                                                                                                                                      Nov 20, 2018: Stallergenes Greer announces that the phase III trial for its sublingual allergy immunotherapy tablet STAGR320 to treat house dust mite-induced allergic rhinitis achieved its primary endpoint

                                                                                                                                                                        May 29, 2018: Allergy Therapeutics - Positive new data with house-dust mite immunotherapy

                                                                                                                                                                          Feb 21, 2018: New medicine for house dust mite allergic rhinitis and allergic asthma now available in France

                                                                                                                                                                            Feb 16, 2018: Shionogi Got Approval of Partial Change Application in Dosage and Administration in Japan of Actair for Allergen Immunotherapy of Pediatric Allergic Rhinitis Caused by House Dust Mites

                                                                                                                                                                              Feb 16, 2018: Torii Receives Approval for Additional Dosage and Administration for Pediatric Indication for MITICURE House Dust Mite Sublingual Tablets

                                                                                                                                                                                Jan 11, 2018: New Treatment for House Dust Mite (HDM) - Induced Allergic Rhinitis Now Available in US

                                                                                                                                                                                  Nov 30, 2017: ALK secures pricing and reimbursement for ACARIZAX in France

                                                                                                                                                                                    Nov 23, 2017: European Patent Office Grants to ASIT biotech a Second Patent Related to the Active Ingredients Used in the ASIT+ Allergy Immunotherapy Product Candidates

                                                                                                                                                                                      Oct 24, 2017: ASIT biotech Publishes the Results of The hdm-ASIT+ Phase I/II Follow-up Study in House Dust Mite Rhinitis

                                                                                                                                                                                        Sep 26, 2017: Stallergenes Greer Advances Its House Dust Mite Allergy Pipeline With Acceptance Of Regulatory Submission And New Market Approval

                                                                                                                                                                                          Aug 21, 2017: ALK to accelerate launches of ODACTRA in the USA / ACARIZAX in Canada

                                                                                                                                                                                            Aug 16, 2017: ASIT biotech Announces the Approval by the Regulatory Authorities of a Follow-up Study of the Phase I/IIa Clinical Trial with its hdm-ASIT Product Candidate for House Dust Mite Rhinitis

                                                                                                                                                                                              Jul 27, 2017: Stallergenes Greer Announces Completion of Enrollment in Largest Phase III Study to Treat House Dust Mites Allergy

                                                                                                                                                                                                Appendix

                                                                                                                                                                                                  Methodology

                                                                                                                                                                                                    Coverage

                                                                                                                                                                                                      Secondary Research

                                                                                                                                                                                                        Primary Research

                                                                                                                                                                                                          Expert Panel Validation

                                                                                                                                                                                                            Contact Us

                                                                                                                                                                                                              Disclaimer

                                                                                                                                                                                                              Summary:
                                                                                                                                                                                                              Get latest Market Research Reports on House Dust Mite Allergy. Industry analysis & Market Report on House Dust Mite Allergy is a syndicated market report, published as House Dust Mite Allergy - Pipeline Review, H2 2019. It is complete Research Study and Industry Analysis of House Dust Mite Allergy market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

                                                                                                                                                                                                              Last updated on

                                                                                                                                                                                                              REPORT YOU MIGHT BE INTERESTED

                                                                                                                                                                                                              Purchase this Report

                                                                                                                                                                                                              $2,000.00
                                                                                                                                                                                                              $4,000.00
                                                                                                                                                                                                              $6,000.00
                                                                                                                                                                                                              1,584.00
                                                                                                                                                                                                              3,168.00
                                                                                                                                                                                                              4,752.00
                                                                                                                                                                                                              1,848.00
                                                                                                                                                                                                              3,696.00
                                                                                                                                                                                                              5,544.00
                                                                                                                                                                                                              302,580.00
                                                                                                                                                                                                              605,160.00
                                                                                                                                                                                                              907,740.00
                                                                                                                                                                                                              166,740.00
                                                                                                                                                                                                              333,480.00
                                                                                                                                                                                                              500,220.00
                                                                                                                                                                                                              Credit card Logo

                                                                                                                                                                                                              Related Reports


                                                                                                                                                                                                              Reason to Buy

                                                                                                                                                                                                              Request for Sample of this report